LIVIVO - Search results -

Search results

Result 1 - 10 of total 232

Search options

Article ; Online: Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.

Rutherford, Sarah C / Yin, Jun / Pederson, Levi D / Blum, Kristie A / Martin, Peter / Jung, Sin-Ho / Grant, Barbara / Rosenbaum, Cara / Cheson, Bruce D / Bartlett, Nancy L / Mandrekar, Sumithra J / Leonard, John P

Blood advances

2024 Volume 8, Issue 6, Page(s) 1464–1468

MeSH term(s)	Humans ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/therapy ; Progression-Free Survival ; Rituximab ; Antibodies, Monoclonal, Murine-Derived ; Diagnostic Imaging
Chemical Substances	Rituximab (4F4X42SYQ6) ; Antibodies, Monoclonal, Murine-Derived
Language	English
Publishing date	2024-01-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023012090
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum.

Richardson, Brittany / Swenson, Sabrina / Hamilton, John / Leonard, Ken / Delis, Foteini / Gold, Mark / Blum, Ken / Thanos, Panayotis K

Progress in neuro-psychopharmacology & biological psychiatry

2021 Volume 112, Page(s) 110407

Abstract: Clinical and preclinical studies have shown dysfunctions in genetic expression and neurotransmission of γ-Aminobutyric acid (GABA), ... ...

Abstract	Clinical and preclinical studies have shown dysfunctions in genetic expression and neurotransmission of γ-Aminobutyric acid (GABA), GABA
MeSH term(s)	Animals ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/pharmacology ; Autoradiography ; Brain/metabolism ; Cerebellum/drug effects ; Diet, High-Fat ; Flunitrazepam/metabolism ; Haloperidol/administration & dosage ; Haloperidol/pharmacology ; Male ; Olanzapine/administration & dosage ; Olanzapine/pharmacology ; Prefrontal Cortex/metabolism ; Radioligand Assay ; Rats ; Schizophrenia/drug therapy ; gamma-Aminobutyric Acid/metabolism
Chemical Substances	Antipsychotic Agents ; gamma-Aminobutyric Acid (56-12-2) ; Flunitrazepam (620X0222FQ) ; Haloperidol (J6292F8L3D) ; Olanzapine (N7U69T4SZR)
Language	English
Publishing date	2021-07-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	781181-0
ISSN	1878-4216 ; 0278-5846
ISSN (online)	1878-4216
ISSN	0278-5846
DOI	10.1016/j.pnpbp.2021.110407
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1342: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Les vies de Pierre Naville

Blum, Françoise

2007

Abstract: ... rencontre avec André Breton et les surréalistes, avec Léon Trotsky, avec Georges Friedmann ...

Abstract	Pierre Naville (1903-1993) fut une figure du surréalisme, puis un militant professionnel, avant d'entamer la rédaction de ses œuvres majeures, et d'acquérir une légitimité scientifique dans le champ de la sociologie. Pour autant, il ne cessa jamais d'être un militant et un écrivain. Cet ouvrage se propose d'analyser une série de rencontres essentielles, réelles et/ou intellectuelles, dans la vie de Naville : rencontre avec André Breton et les surréalistes, avec Léon Trotsky, avec Georges Friedmann, mais aussi avec Paul Thiry d'Holbach ou John Broadus Watson.... Cette démarche permet ainsi de mieux comprendre la position de ce riche héritier en capital social et culturel dans les différents champs du savoir (politique, littéraire et sociologique), et la façon dont il se situe au cœur de réseaux qui se recoupent, se croisent et s'alimentent les uns les autres. Ce livre offre donc, outre une archéologie des savoirs, des pratiques et des affinités de Pierre Naville, une contribution à la connaissance de la construction, du fonctionnement et de l'imbrication de ces réseaux eux-mêmes : réseaux familiaux, réseaux militants, réseaux intellectuels, réseaux professionnels
Keywords	Arts in general ; History (General)
Size	1 electronic resource ( pages)
Publisher	Presses universitaires du Septentrion
Document type	Book ; Online
Note	French ; Open Access
HBZ-ID	HT020677764
ISBN	9782757422717 ; 2757422715
DOI	10.4000/books.septentrion.56594
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online ; Thesis: Charakterisierung neuartiger immunmodulierender Wirkstoffkandidaten

Blum, Leonard Christoph [Verfasser] / Schubert-Zsilavecz, Manfred [Gutachter] / Schiffmann, Susanne [Gutachter]

2020

Author's details	Leonard Christoph Blum ; Gutachter: Manfred Schubert-Zsilavecz, Susanne Schiffmann
Keywords	Medizin, Gesundheit ; Medicine, Health
Subject code	sg610
Language	German
Publisher	Universitätsbibliothek Johann Christian Senckenberg
Publishing place	Frankfurt am Main
Document type	Book ; Online ; Thesis
Database	Digital theses on the web

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: André Gide & Léon Blum

Gide, André / Blum, Léon / Lachasse, Pierre

Correspondance 1890-1950. Nouvelle édition augmentée

(André Gide - Textes et correspondances)

2011

Series title	André Gide - Textes et correspondances
Keywords	Literary studies: general ; littérature française ; antisémitisme ; politique ; littérature ; littérature épistolaire ; XXe siècle ; lettre
Language	0\|f
Size	1 electronic resource (278 pages)
Publisher	Presses universitaires de Lyon
Publishing place	Lyon
Document type	Book ; Online
Note	French ; Open Access
HBZ-ID	HT021617102
ISBN	9782729708450 ; 2729708456
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).

LaCasce, Ann S / Dockter, Travis / Ruppert, Amy S / Kostakoglu, Lale / Schöder, Heiko / Hsi, Eric / Bogart, Jeffrey / Cheson, Bruce / Wagner-Johnston, Nina / Abramson, Jeremy / Blum, Kristie / Leonard, John P / Bartlett, Nancy L

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022 Volume 41, Issue 5, Page(s) 1023–1034

Abstract: Purpose: Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation. Late effects associated with radiotherapy include increased risk of second cancer and cardiovascular disease. We tested ...

Abstract	Purpose: Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation. Late effects associated with radiotherapy include increased risk of second cancer and cardiovascular disease. We tested a positron emission tomography (PET)-adapted approach in patients with bulky, early-stage cHL, omitting radiotherapy in patients with interim PET-negative (PET-) disease and intensifying treatment in patients with PET-positive (PET+) disease. Methods: Eligible patients with bulky disease (mass > 10 cm or 1/3 the maximum intrathoracic diameter on chest x-ray) received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim fluorodeoxyglucose PET (PET2). Patients with PET2-, defined as 1-3 on the 5-point scale, received four additional cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Patients with PET2+ received four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone followed by 30.6 Gy involved-field radiation. Results: Of 94 evaluable patients, 53% were female with median age 30 years (range, 18-58 years). Eight-five (90%) had stage II disease, including 48 (51%) with stage IIB/IIBE. Seventy-eight (78%) were PET2- and 21 (22%) were PET2+. The predominant toxicity was neutropenia, with 9% of patients developing febrile neutropenia and one developing sepsis. The primary end point of 3-year progression-free survival (PFS) was 93.1% in PET2- and 89.7% in PET2+ patients. Three-year overall survival was 98.6% and 94.4%, respectively. The estimated hazard ratio comparing PFS of patients with PET2+ and patients with PET2- was 1.03 (85% upper bound 2.38) and was significantly less than the null hypothesis of 4.1 (one-sided Conclusion: Our study of PET-adapted therapy in bulky stage I/II cHL met its primary goal and was associated with an excellent 3-year PFS rate of 92.3% in all patients, with the majority being spared radiotherapy and exposure to intensified chemotherapy.
MeSH term(s)	Humans ; Female ; Adult ; Male ; Hodgkin Disease/drug therapy ; Vinblastine ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Doxorubicin ; Bleomycin ; Dacarbazine ; Neoplasm Staging ; Positron-Emission Tomography/methods ; Vincristine ; Prednisone
Chemical Substances	Vinblastine (5V9KLZ54CY) ; Doxorubicin (80168379AG) ; Bleomycin (11056-06-7) ; Dacarbazine (7GR28W0FJI) ; Vincristine (5J49Q6B70F) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2022-10-21
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.22.00947
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.

Blum, Leonard / Geisslinger, Gerd / Parnham, Michael J / Grünweller, Arnold / Schiffmann, Susanne

Journal of cellular and molecular medicine

2020 Volume 24, Issue 12, Page(s) 6988–6999

Abstract: Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new ... ...

Abstract	Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new antiviral drug candidate silvestrol effectively inhibited replication of Corona-, Ebola-, Zika-, Picorna-, Hepatis E and Chikungunya viruses. Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens. In the present study, silvestrol down-regulated several pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, CCL2, CCL18) and increased TNF-α during differentiation and activation of M1-macrophages, suggesting that the effects of silvestrol might cancel each other out. However, silvestrol amplified the anti-inflammatory potential of M2-macrophages by increasing expression of anti-inflammatory surface markers CD206, TREM2 and reducing release of pro-inflammatory IL-8 and CCL2. The differentiation of dendritic cells in the presence of silvestrol is characterized by down-regulation of several surface markers and cytokines indicating that differentiation is impaired by silvestrol. In conclusion, silvestrol influences the inflammatory status of immune cells depending on the cell type and activation status.
MeSH term(s)	Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/growth & development ; Betacoronavirus/immunology ; Cell Differentiation/drug effects ; Chikungunya virus/drug effects ; Chikungunya virus/growth & development ; Chikungunya virus/immunology ; Cytokines/classification ; Cytokines/genetics ; Cytokines/immunology ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Dendritic Cells/virology ; Ebolavirus/drug effects ; Ebolavirus/growth & development ; Ebolavirus/immunology ; Gene Expression Profiling ; Gene Expression Regulation/drug effects ; Hepatitis E virus/drug effects ; Hepatitis E virus/growth & development ; Hepatitis E virus/immunology ; Humans ; Immunity, Innate/drug effects ; Immunologic Factors/pharmacology ; Macrophages/drug effects ; Macrophages/immunology ; Macrophages/virology ; Organ Specificity ; Picornaviridae/drug effects ; Picornaviridae/growth & development ; Picornaviridae/immunology ; Primary Cell Culture ; SARS-CoV-2 ; Signal Transduction ; Triterpenes/pharmacology ; Zika Virus/drug effects ; Zika Virus/growth & development ; Zika Virus/immunology
Chemical Substances	Antiviral Agents ; Cytokines ; Immunologic Factors ; Triterpenes ; silvestrol
Keywords	covid19
Language	English
Publishing date	2020-05-06
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2074559-X
ISSN	1582-4934 ; 1582-4934 ; 1582-1838
ISSN (online)	1582-4934
ISSN	1582-4934 ; 1582-1838
DOI	10.1111/jcmm.15360
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5752: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The immunomodulatory potential of the arylmethylaminosteroid sc1o.

Blum, Leonard / Ulshöfer, Thomas / Henke, Marina / Krieg, Reimar / Berneburg, Isabell / Geisslinger, Gerd / Becker, Katja / Parnham, Michael J / Schiffmann, Susanne

Journal of molecular medicine (Berlin, Germany)

2020 Volume 99, Issue 2, Page(s) 261–272

Abstract: Developing resistance mechanisms of pathogens against established and frequently used drugs are a growing global health problem. Besides the development of novel drug candidates per se, new approaches to counteract resistance mechanisms are needed. Drug ... ...

Abstract	Developing resistance mechanisms of pathogens against established and frequently used drugs are a growing global health problem. Besides the development of novel drug candidates per se, new approaches to counteract resistance mechanisms are needed. Drug candidates that not only target the pathogens directly but also modify the host immune system might boost anti-parasitic defence and facilitate clearance of pathogens. In this study, we investigated whether the novel anti-parasitic steroid compound 1o (sc1o), effective against the parasites Plasmodium falciparum and Schistosoma mansoni, might exhibit immunomodulatory properties. Our results reveal that 50 μM sc1o amplified the inflammatory potential of M1 macrophages and shifted M2 macrophages in a pro-inflammatory direction. Since M1 macrophages used predominantly glycolysis as an energy source, it is noteworthy that sc1o increased glycolysis and decreased oxidative phosphorylation in M2 macrophages. The effect of sc1o on the differentiation and activation of dendritic cells was ambiguous, since both pro- and anti-inflammatory markers were regulated. In conclusion, sc1o has several immunomodulatory effects that could possibly assist the immune system by counteracting the anti-inflammatory immune escape strategy of the parasite P. falciparum or by increasing pro-inflammatory mechanisms against pathogens, albeit at a higher concentration than that required for the anti-parasitic effect. KEY MESSAGES: • The anti-parasitic steroid compound 1o (sc1o) can modulate human immune cells. • Sc1o amplified the potential of M1 macrophages. • Sc1o shifts M2 macrophages to a M1 phenotype. • Dendritic cell differentiation and activation was ambiguously modulated. • Administration of sc1o could possibly assist the anti-parasitic defence.
MeSH term(s)	Antiparasitic Agents/pharmacology ; Cell Differentiation/drug effects ; Cell Survival/drug effects ; Cells, Cultured ; Dendritic Cells/drug effects ; Dendritic Cells/metabolism ; Energy Metabolism/drug effects ; Humans ; Immunologic Factors/pharmacology ; Macrophages/drug effects ; Macrophages/metabolism ; Steroids/pharmacology
Chemical Substances	Antiparasitic Agents ; Immunologic Factors ; Steroids ; arylmethylaminosteroid 1o
Language	English
Publishing date	2020-12-17
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1223802-8
ISSN	1432-1440 ; 0946-2716
ISSN (online)	1432-1440
ISSN	0946-2716
DOI	10.1007/s00109-020-02024-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.36: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.

Blood advances

2022 Volume 6, Issue 9, Page(s) 2745–2756

Abstract: Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLBCL) have shown negative results, which may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require ... ...

Abstract	Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLBCL) have shown negative results, which may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require immediate treatment. We conducted a Delphi-method survey with lymphoma experts in the United States to define recommendations for essential and potentially unnecessary enrollment criteria for modern first-line DLBCL RCTs aimed at increasing clinical diversity of ensuing study groups. We first tabulated enrollment criteria from 19 DLBCL RCTs spanning the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) era to identify common eligibility criteria from prior DLBCL RCTs for inclusion in the Delphi-method survey. We tabulated 451 total eligibility criteria comprising 51 criterion categories across 19 first-line DLBCL RCTs in the R-CHOP era. We then surveyed lymphoma clinical trial experts representing 8 academic medical centers in the United States regarding essential and unnecessary eligibility criteria for modern DLBCL RCTs. Seventeen of 29 invited clinical investigators completed the round-1 questionnaire (response rate, of 58.6%), 15 of 17 round-1 participants (88.2%) completed the round-2 survey, and all round-1 participants reviewed finalized recommendations for eligibility criteria for modern first-line DLBCL RCTs. We defined consensus recommendations for 31 modernized eligibility criteria including threshold values for 10 quantitative eligibility criteria aimed at facilitating enrollment of a clinically diverse study population in first-line DLBCL RCTs designed to improve standard-of-care therapy.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide ; Doxorubicin ; Humans ; Lymphoma, Large B-Cell, Diffuse/pathology ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Rituximab ; Surveys and Questionnaires ; Vincristine
Chemical Substances	Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2022-02-03
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2021006504
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

Thanarajasingam, Gita / Leonard, John P / Witzig, Thomas E / Habermann, Thomas M / Blum, Kristie A / Bartlett, Nancy L / Flowers, Christopher R / Pitcher, Brandelyn N / Jung, Sin-Ho / Atherton, Pamela J / Tan, Angelina / Novotny, Paul J / Dueck, Amylou C

The Lancet. Haematology

2020 Volume 7, Issue 6, Page(s) e490–e497

Abstract: Evaluation of tolerability is increasingly relevant for patients with haematological malignancies treated with chronically administered therapies. Adverse events from these agents might affect the ability of patients to tolerate treatment over time. ... ...

Abstract	Evaluation of tolerability is increasingly relevant for patients with haematological malignancies treated with chronically administered therapies. Adverse events from these agents might affect the ability of patients to tolerate treatment over time. Conventional toxicity tables that include the incidence of high-grade adverse events, defined by the Common Terminology Criteria for Adverse Events, do not provide information on the time profile of these adverse events or reflect the continuous, lower grade symptomatic toxicities that are particularly relevant to treatment tolerability for patients living with indolent disease. Modern approaches to the evaluation and reporting of toxicity that capture the tolerability of treatment to the patient are imperative. In this Viewpoint, we present a focused, pilot, and longitudinal Toxicity over Time analysis of adverse events from lenalidomide and lenalidomide with rituximab in patients with follicular lymphoma treated in the CALGB 50401 (Alliance; NCT00238238) trial to define the trajectory of adverse events and quantify the burden of continuous, low-grade events. Toxicity over Time analyses provided clinically relevant descriptions of neutropenia and fatigue trajectories caused by lenalidomide that were not identified by standard analysis of the maximum grade events defined by the Common Terminology Criteria for Adverse Events. Systematic, rigorous incorporation of patient-reported outcomes in clinical trials will be crucial to our understanding of the tolerability of chronically administered therapies in patients with haematological malignancies.
MeSH term(s)	Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/toxicity ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Drug Tolerance/physiology ; Fatigue/chemically induced ; Fatigue/classification ; Fatigue/epidemiology ; Hematologic Neoplasms/drug therapy ; Humans ; Infusions, Intravenous ; Lenalidomide/adverse effects ; Lenalidomide/toxicity ; Lymphoma, Follicular/drug therapy ; Neutropenia/chemically induced ; Neutropenia/classification ; Neutropenia/epidemiology ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Thrombosis/chemically induced ; Thrombosis/classification ; Thrombosis/epidemiology
Chemical Substances	Angiogenesis Inhibitors ; Antineoplastic Agents, Immunological ; Rituximab (4F4X42SYQ6) ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2020-06-09
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
ISSN	2352-3026
ISSN (online)	2352-3026
DOI	10.1016/S2352-3026(20)30067-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED